Sai Life Sciences is a major player in the contract research, development, and manufacturing organization market. The company’s financials and fundamentals are also looking strong, which is a major attraction for investors. If you are also interested in the stock, predicting Sai Life Sciences’ share price target for 2025, 2026, and 2027 can help you generate high profits.
As per the industry outlook, there is a huge opportunity in the industry due to its high growth rate in the coming years. With deep analysis, it will become easy to generate a good return from the Sai Life Sciences stock in the short-term to long term.
Free Stocks & IPO GMP
- IPO GMP: Get IPO GMP (Grey Market Premium) of current IPOs directly on WhatsApp.
- Best Stocks: Based on current market and industry conditions, find the best stocks for short-term or long-term investment.
- Free Stocks: Get short-term stocks for short-term investing from top brokers and researchers, including Anand Rathi, Motilal Oswal, Sharekhan, ICICI Securities, Phabhudas Lilladher, and others.
Related Posts:
- MobiKwik Share Price Target 2025, 2026, and 2027
- Vishal Mega Mart Share Price Target 2025, 2026, and 2027
- Jio Financial Services Share Price Target 2025, 2026, and 2027
About Sai Life Sciences Ltd
Sai Life Sciences Ltd company was incorporated in 1999. It is a healthcare services sector company that works in a few countries and has manufacturing facilities in the US, UK, and India. Locations are Discovery Biology Lab (Greater Boston, USA), Process R&D Lab (Manchester, UK), Integrated Campus Hyderabad, and API Manufacturing Facility, Bidar, India.
As per the FY24 report, the company recently (in FY24) completed 200+ discovery programs, and 40+ programs advanced to the clinical phase. Sai Life Sciences Ltd company provides its services to the top 17 (out of 20) pharmaceutical companies and biotechnology companies.
Discover or services of the Sai Life Sciences company are DMPK (Drug Metabolism and Pharmacokinetics), Genotoxicity, General Toxicology, Biology Services, Computational Chemistry, Integrated drug discovery, and Synthetic & Medicinal Chemistry.
In FY24, the company generated 66% revenue from the contract and manufacturing service and the remaining 34% revenue from contract research. The company generates maximum revenue by exporting, it generated nearly 98% revenue from exports and the rest from domestically.
Sai Life Sciences Ltd’s Scrip Info
| NSE | SAILIFE |
| BSE | 544306 |
| ISIN | INE570L01029 |
| SECTOR | HEALTHCARE |
Stock Insights & Key Metrics
Check the most important and helpful data and information that are helpful in the analysis of any stock. Here, you’ll get Sai Life Sciences Ltd.’s Financials, Fundamentals, Shareholding Pattern, Pros and Cons, Quarterly Results, etc.
Note: This shared data and information are not enough for complete analysis. You can check new and updated information about the company by clicking on the button.
Note: All the values are in Rupees (₹) Crores.
| Quarter | Net Profit & Loss |
|---|---|
| Sep 2023 | ₹N/A |
| Dec 2023 | ₹N/A |
| Mar 2024 | ₹N/A |
| Jun 2024 | ₹N/A |
| Sep 2024 | ₹N/A |
| Financial Year | Net Profit & Loss |
|---|---|
| March 2020 | ₹NA |
| March 2021 | ₹82 Crore |
| March 2022 | ₹10 Crore |
| March 2023 | ₹16 Crore |
| March 2024 | ₹109 Crore |
| Market Cap | ₹11,419 Crore | ROE | 8.89% |
| P/E Ratio TTM | 138 | EPS (TTM) | NA |
| P/B Ratio | NA | Div. Yield | 0.00% |
| Industry PE | 57.7 | Book Value | NA |
| Debt To Equity | NA | Face Value | NA |
| Held By | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|
| FIIs | NA | NA | NA |
| DIIs | NA | NA | NA |
| Public | NA | NA | NA |
| Promoters | NA | NA | NA |
| Other Holders | NA | NA | NA |
Key Points
- Zero promoter pledge.
- Low debt on the company.
- Sai Life Sciences is making a profit consistently.
- The company generates maximum revenue from exports.
- Over the years, the company’s profit and revenue improved.
- 3 years of compounded sales growth of the company is 24%.
- 3 years of compounded profit growth of the company is 11%.
Sai Life Sciences Share Price Target
Considering the Sai Life Sciences stock for long-term investing can be a good idea as the company is consistently making a profit and over the years the annual net profit and revenue of the company has increased rapidly. March 2024 annual net profit is almost 11X as compared to March 2022.
In other words, you can say that the company is fundamentally and financially strong. The industry is likely to grow rapidly in the coming years and will also boost the stock price of the company.
| Year | Min. Estimated Target | Max. Estimated Target |
|---|---|---|
| 2025 | ₹700 | ₹900 |
| 2026 | ₹1000 | ₹1200 |
| 2027 | ₹1200 | ₹1500 |
Disclaimer: AskDhan or we are not SEBI registered, and this is not a Buying or Selling recommendation. We will not be responsible for any loss or profit. This post is only for educational and learning purposes. All the targets given in the post are based on news, brokerage research, technical analysis, etc. We strongly recommend you talk to your financial advisor before making any decision.
Sai Life Sciences Share Price Target 2025
Sai Life Sciences stock is listed in the NSE and BSE on 18 December 2024. The stock was listed at a premium of 20%, which was expected as its IPO GMP was also trading near a 20-30% premium. It is listed in the market at Rs. 650.
After listing in the market, they faced huge buying pressure and started going up just after listing. Currently, the stock is trading at Rs. more than 17% from its listing price and more than 39% from its IPO price band.
Currently, the stock is very bullish, and most probably the stock will continue going up in the next few trading days. In the bull run, Sai Life Sciences could touch the share price target of Rs. 850 to Rs. 900.
Note: This type of trend is only for short term, trading in the trend is very risky due to massive buying and selling.
Sai Life Sciences Share Price Target 2026 and 2027
As mentioned earlier, the Sai Life Sciences stock is good for the long term as per the industry growth forecast, strong fundamentals, financials, top clients, etc. But the return depends on the at what valuation and stock price you bought the stock, buying any stock at any price can reduce your profit. Let’s check all the points as per the stock is good for the long term.
Annual Profit and Loss, There are 4 years of annual profit and loss data available in a row. In March 2021 the company made a net profit of Rs. 82 Crore, In March 2022 Rs. 10 Crore, In March 2023 Rs. 16 Crore, and in March 2024 Rs. 109 Crore.
As per reports and predictions, the global pharmaceutical market is forecasted to grow at 6.2% CAGR by 2028 and its market size can reach $1,956 billion. The contract research, development, and manufacturing market is also forecasted to grow by 14% annually. As Sai Life Sciences is a major player in the industry, the industry and market growth will also benefit it.
The company will invest raised money through IPO to repay or prepay outstanding borrowings and general corporate purposes. This will increase the profitability of the company in the long term.
In short, it is a good stock for the long term as per industry outlook, fundamentals, financials, etc. You can see Sai Life Sciences’ share price target for 2026 and 2027 near Rs. 1200 to Rs. 1500.
FAQs
Sai Life Sciences is listed at a 20% premium and trading at more than 19% from its listing price. Overall the stock is trading nearly 40% up from its listing price as of 18 December 2024.
In the current trend, you can expect a target of Rs. 850 to 900, buying at this level is not recommended as it is trading at a record high. This trend is only for short-term, after a few weeks the stock may fall.
The Industry outlook or forecasted data is amazing in both countries US and India. The Sai Life Sciences is one of the major players in the industry and its top 17 clients come under the top 20 list. The industry growth is likely to give a massive share price boost to the company.
1. Global pharmaceutical market is forecasted to grow at 6.2% CAGR by 2028 and its market size can reach $1,956 billion.
2. The contract research, development, and manufacturing market is also forecasted to grow by 14% annually.
Yes, Sai Life Sciences Ltd company is good for the long term due to high industry growth by 2028, strong company fundamentals and financials, low debt, and many more.
But the actual point is, at what price you are buying the stock? if you buy the stock at a higher price you may not get good profits or face huge losses during the bearish market. So, it is recommended to buy stock when it is available at a good valuation and avoid buying in bulk.
The Bottom Line
Sai Life Sciences Ltd is engaged in the business of contract research, development, and manufacturing organizations in the pharmaceutical and biotechnology industries. The company is highly profitable and its top 17 clients are from the top 20 players of the pharmaceutical companies and many bio-technology companies. The industry is forecasted to grow rapidly till 2028. As a result, the Sai Life Sciences share price target for 2025, 2026, and 2027 may give massive returns.